Campbell Capital Management Inc. Sells 914 Shares of Bristol-Myers Squibb (NYSE:BMY)

Campbell Capital Management Inc. cut its position in Bristol-Myers Squibb (NYSE:BMY) by 0.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 106,367 shares of the biopharmaceutical company’s stock after selling 914 shares during the quarter. Bristol-Myers Squibb comprises approximately 3.1% of Campbell Capital Management Inc.’s holdings, making the stock its 12th biggest position. Campbell Capital Management Inc.’s holdings in Bristol-Myers Squibb were worth $6,715,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Retirement Group LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $27,000. Orion Capital Management LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $28,000. Perennial Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $29,000. Founders Capital Management acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $31,000. Finally, Alpha DNA Investment Management LLC acquired a new stake in Bristol-Myers Squibb during the 4th quarter valued at $33,000. 72.41% of the stock is owned by institutional investors and hedge funds.

In other Bristol-Myers Squibb news, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $62.20, for a total value of $1,555,000.00. Following the transaction, the chief executive officer now owns 528,980 shares in the company, valued at $32,902,556. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.14% of the company’s stock.

BMY stock traded up $0.13 during midday trading on Thursday, reaching $62.19. The company had a trading volume of 166,661 shares, compared to its average volume of 12,768,893. The company has a market capitalization of $138.93 billion, a price-to-earnings ratio of -564.13, a price-to-earnings-growth ratio of 1.00 and a beta of 0.67. The stock has a 50 day moving average price of $61.76 and a 200-day moving average price of $65.68. Bristol-Myers Squibb has a 1-year low of $54.07 and a 1-year high of $67.16. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Wednesday, February 3rd. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the Zacks’ consensus estimate of $1.42 by $0.04. The business had revenue of $11.07 billion during the quarter, compared to the consensus estimate of $10.74 billion. Bristol-Myers Squibb had a positive return on equity of 27.48% and a negative net margin of 0.11%. Bristol-Myers Squibb’s revenue for the quarter was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.22 earnings per share. As a group, research analysts anticipate that Bristol-Myers Squibb will post 6.35 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, May 3rd. Shareholders of record on Thursday, April 1st will be given a $0.49 dividend. This represents a $1.96 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date of this dividend is Wednesday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is presently 41.79%.

Several brokerages have issued reports on BMY. Zacks Investment Research raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price target for the company in a report on Tuesday. TheStreet downgraded Bristol-Myers Squibb from a “b” rating to a “c” rating in a report on Monday, March 8th. Finally, The Goldman Sachs Group raised Bristol-Myers Squibb from a “buy” rating to a “conviction-buy” rating in a report on Tuesday, December 15th. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $74.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Read More: Initial Coin Offering (ICO)

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.